This compound was the first SMO inhibitor, developed by pharmaceutical Curis and Genetech, and it has been successfully employed in clinical oncology for treating medulloblastoma and BCC by inhibiting activation of the Hh pathway [83, 84]. The gene discussed is SMO; the disease is skin basal cell carcinoma.